Request for Applications: ALS Association’s Quality of Care Research Awards (2023)

The ALS Association’s Quality of Care Research Awards provide up to $500,000 over two years to support the development and/or testing of interventions intended to improve quality of life; make ALS care safer, of higher quality, more accessible, more equitable, and more affordable; and enhance service delivery at the point of care.  

We are interested in applications from all scientific disciplines on topics including, but not limited to:

• Optimizing existing therapies, such as developing and/or testing interventions to improve quality at the point of care, optimizing combinations of FDA-approved disease-modifying drug treatments, or developing and/or testing protocols to improve the efficiency of intrathecal medication administration and/or reduce side effects.
• Reducing complications by developing and/or testing care interventions focused on reducing falls, pneumonia, emergency room visits, respiratory failure, sialorrhea, etc.; care interventions intended to address nutritional needs, respiratory management, coping, isolation, medication alignment, or palliative care; strategies to reduce caregiver burden; or protocols for symptom management and end-of-life care.
• Improving systems and services including developing and/or testing interventions intended to reduce racial, ethnic, geographic, gender, or other disparities in diagnosis, access to care, and treatment outcomes; strategies to reduce time to diagnosis; interventions to increase utilization of evidence-based practices; telehealth or telemedicine approaches; strategies to improve quality of care for people with ALS being managed in their community; or support systems, education, or programs for health care professionals to manage fatigue and the emotional distress they encounter in ALS practice.

We encourage collaboration between implementation science, quality improvement, and health services researchers and ALS clinician-scientists. 

For more information, visit here.